Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) [Breast Cancer]
Conclusion
The addition of bevacizumab to letrozole improved PFS in hormone receptor–positive MBC, but this benefit was associated with a markedly increased risk of grade 3 to 4 toxicities. Research on predictive markers will be required to clarify the role of bevacizumab in this setting.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Dickler, Barry, Cirrincione, Ellis, Moynahan, Innocenti, Hurria, Rugo, Lake, Hahn, Schneider, Tripathy, Carey, Winer, Hudis Tags: Hormonal Therapy Breast Cancer Source Type: research
More News: Avastin | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hormonal Therapy | Hormones | Hypertension | Proteinuria | Toxicology | Women